Prof. Dr. Dr. med. Felix Sahm joins as Chief Medical Advisor, guiding clinical and medical strategy as the company expands its precision diagnostics portfolio.

A substantial update to the sarcoma tumour classifier, extending precision methylation-based classification beyond tumours of the central nervous system.

Helge Lubenow becomes Chief Executive Officer, succeeding founder David Jones, who continues with the company as Chief Scientific Officer.